Huadong Medicine Co., Ltd (SHE: 000963), a biopharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with clinical trials for HDM2005, an antibody-drug conjugate (ADC) that targets the recombinant receptor tyrosine kinase-like orphan receptor 1 (ROR1). The molecule is intended for use in treating a broad spectrum of advanced malignant tumors.
Preclinical studies have demonstrated that HDM2005’s antibody component specifically binds to cancer cells that express certain tumor antigens. Once HDM2005 is internalized by these tumor cells, it releases cytotoxic agents within the cell, effectively targeting and killing the cancer cells. Available data indicates that HDM2005 exhibits favorable pharmacological properties and a robust safety profile.- Flcube.com
